Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
25
3
2021
Statut:
epublish
Résumé
There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality-and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management. Funding was obtained by each of the participating cohorts individually.
Sections du résumé
BACKGROUND
BACKGROUND
There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium.
METHOD
METHODS
The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors.
FINDINGS
RESULTS
We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors.
INTERPRETATION
CONCLUSIONS
The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality-and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management.
FUNDING
BACKGROUND
Funding was obtained by each of the participating cohorts individually.
Identifiants
pubmed: 33758887
doi: 10.1101/2021.03.07.21252875
pmc: PMC7987046
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Liver Res. 2021 Mar;5(1):21-27
pubmed: 33520337
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Int J Public Health. 2020 Nov;65(8):1435-1436
pubmed: 32978645
EClinicalMedicine. 2020 Aug;25:100464
pubmed: 32838237
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Nature. 2010 Sep 2;467(7311):52-8
pubmed: 20811451
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Comput Struct Biotechnol J. 2021;19:976-988
pubmed: 33558827
Nat Med. 2020 May;26(5):640-642
pubmed: 32273610
Am J Emerg Med. 2021 Feb;40:11-14
pubmed: 33333477
Nature. 2020 Nov;587(7835):610-612
pubmed: 32998156
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nat Rev Rheumatol. 2020 Oct;16(10):581-589
pubmed: 32733003
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Eur J Hum Genet. 2020 Jun;28(6):715-718
pubmed: 32404885
Signal Transduct Target Ther. 2021 Feb 22;6(1):85
pubmed: 33619245
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660
pubmed: 33382671
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901